Thrivent Financial for Lutherans Has $230.67 Million Stock Position in Johnson & Johnson $JNJ

Thrivent Financial for Lutherans raised its holdings in Johnson & Johnson (NYSE:JNJ) by 2.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,510,207 shares of the company’s stock after buying an additional 40,239 shares during the quarter. Johnson & Johnson accounts for 0.5% of Thrivent Financial for Lutherans’ investment portfolio, making the stock its 24th largest holding. Thrivent Financial for Lutherans owned about 0.06% of Johnson & Johnson worth $230,670,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Clark Asset Management LLC increased its stake in Johnson & Johnson by 51.6% during the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after purchasing an additional 3,025 shares in the last quarter. Treasurer of the State of North Carolina grew its holdings in shares of Johnson & Johnson by 8.3% during the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after buying an additional 94,957 shares during the last quarter. Apexium Financial LP increased its position in shares of Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after acquiring an additional 2,310 shares in the last quarter. Avanza Fonder AB raised its holdings in shares of Johnson & Johnson by 2.9% in the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after acquiring an additional 6,566 shares during the last quarter. Finally, Winnow Wealth LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at about $295,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.8%

Shares of NYSE:JNJ opened at $211.65 on Monday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $212.27. The company has a market capitalization of $509.93 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 2.36 and a beta of 0.36. The business has a fifty day moving average price of $196.09 and a two-hundred day moving average price of $177.42. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Analysts Set New Price Targets

A number of analysts have commented on JNJ shares. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Citigroup upped their price target on Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a report on Thursday. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Finally, Argus set a $210.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 15th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $207.55.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.